Variable | Unadjusted OR | 95%CI | p-value | Adjusted OR | 95%CI | p-value |
---|---|---|---|---|---|---|
Female gender | 0.91 | 0.36 – 2.35 | 0.86 | †|  |  |
Age at treatment start (months) | 1.00 | 0.99 – 1.01 | 0.81 | †|  |  |
WHO stage 2&3 (vs WHO stage 4) | 2.80 | 1.07 – 7.35 | 0.04 | * |  |  |
Weight-for-age z-score | 1.29 | 0.94 – 1.77 | 0.12 | * |  |  |
Height-for-age z-score | 1.07 | 0.74 – 1.54 | 0.71 | * |  |  |
Weight-for-height z-score | 1.94 | 1.27 – 2.96 | 0.002 | 1.8 | 1.15 – 2.80 | 0.01 |
CD4 percent | 1.04 | 0.97 – 1.12 | 0.27 | * |  |  |
CD4 absolute (cells/l) | 1.44 | 0.54 – 3.84 | 0.47 | * |  |  |
Log viral load | 0.87 | 0.48 – 1.60 | 0.66 | * |  |  |
Ritonavir-containing regimen | 0.33 | 0.13 – 0.87 | 0.03 | †|  |  |
Annual average MR adherence ≥ 90% | 10.30 | 1.92 – 55.67 | 0.005 | 5.48 | 0.84 – 35.58 | 0.075 |